medigraphic.com
ISSN 0210-5187 (Electronic)

2005, Number 3

<< Back Next >>

Med Cutan Iber Lat Am 2005; 33 (3)

Ashy dermatosis (Erythema dischromicum perstans)

López-Bárcenas A, Contreras-Ruíz J, Carrillo-Correa M, Hojyo-Tomoka MT, Arenas R, Domínguez-Soto L, Vega-Memije E

Language: Spanish
References: 22
Page: 97-102
PDF size: 315.79 Kb.


ABSTRACT

The ashy dermatosis (AD) is an idiopathic acquired blue-gray macular hypermelanosis, widespread, that appears in healthy individuals. It was first described by Oswaldo Ramírez from El Salvador in 1957. The etiology of the AD remains unknown; it´s more common in Latin America and Asia, though cases have been described worldwide. It affects both sexes, most commonly dark skin individuals, in the second decade of the life. The AD has a chronic and asymptomatic course with a long evolution, with just cosmetic importance. It usually affects the trunk, arms, neck and face, rarely the exposed areas. The differential diagnosis must be done especially with the lichen planus pigmentosus and idiopathic macular eruptive pigmentation. The histopatology shows a lightly smoothed epidermis with areas of vacuolization and hyperpigmentation of the basal cell layer, with scanty perivascular limphocytic infiltration. There are many therapeutic options, but few of them are effective. The only treatment that apparently has been more effective is clofazimine using an average dose of 100 mg three times per week during three to five months.


REFERENCES

  1. Mosher DB, Fitzpatrick TB, Ortonne JP, Hori Y. Dermatología en medicina general. Quinta edición. Argentina. Editorial Médica Panamericana. 2001:1058.

  2. Vega-Memije ME, MD., Waxtein L, M.D., Arenas R, M.D., Hojyo-Tomak MT, M.D., Domínguez-Soto L. Ashy dermatosis and lichen planus pigmentosus: a clinicopathologic study of 31 cases. Int J Dermatol 1992;31:90-4.

  3. Schwartz R, Erythema Dischromicum Perstans. www.emedicine.com/derm/topic132.htm. 2001.

  4. Convit J, M.D., Piquero-Martín J, M.D., Pérez R, M.D. Erythema Dyschromicum Perstans. Int J Dermatol 1989;28:168-9.

  5. Combemale P, Faisant M, Guennoc B, Duplin M, Jean-Denis Heyraud. Erythema Dyschromicom Perstans: Report of a new case and critical review of the literature. J Dermatology 1998;25:747-53.

  6. Novick L N, Phelps R Erythema Dyschromicum Perstans. Int J Dermatol 1985;24:630-3

  7. Knox J, Billy C, Freeman R. Erythema Dyschromicum Perstans. Arch Dermatal 1968;97:263-72

  8. Carvajal Huerta L, Uraga Pazmiño E, Loayza Vivanzo E, Sabando Sánchez R, García Ahaga I, Jeny E. Dermatitis Cenicienta. Med Cutan Iber Lat Am 1986;14:95-9

  9. Domínguez-Soto L, Hojyo-Tomoka T, Vega-Memije E, Arenas R, Cortes-Franco R. Pigmentary problems in the tropics. Dermatol Clinics 1994;12:777-84

  10. Vega E, Waxtein L, Arenas R, Hojyo-Tomoka T, Domínguez-Soto. L Ashy Dermatosis versus lichen planus pigmentosus: a controversial matter. Int J Dermatol 1992;31: 87-8

  11. Miyagawa S, Komatsu M, Okuchi T, Shirai T, Sakamoto K. Erythema Dyschromicum perstans Immunopathologic studies. J Am Acad Dermatol 1989;20:882-6

  12. Tschen J, Tschen E, McGavran M Erythema Dyschromicum Perstans. J Am Acad Dermatol 1980;4:295-302

  13. Arenas R, Bautista M. Dermatosis Cenicienta. Estudio de 8 pacientes tratados con clofazimina. Rev Colombiana Dermatol 1992;1:103-5

  14. Arenas R. Atlas Diagnóstico y Tratamiento Dermatología. 2a Ed. México. Interamericana-McGraw-Hill Casa Editorial México 1996:92-3

  15. Navarro Jiménez B, Sánchez Navarro L. Dermatosis Cenicienta (Erythema Dyschromicum Perstans): Estudio Prospectivo de 23 pacientes. Med Cut Iber Lat Am 1988;16:407-12.

  16. Berger R, Hayes T, Dixon S. Erythema Dyschromicum Perstans and lichen planus : Are they related?. J Am Acad Dermatol 1989;21:438-442.

  17. Leonforte J, Pelaez de Di B.O. Eritema discrómico persistente versus liquen plano. Med Cutan Iber Lat Am 1987;15:89-92

  18. Sánchez NP, Pathak MA,, Syozo S. Sato, Sánchez JL, Mihm MC, Fitzpatrick TB, Circumscribed Dermal Melaninoses: Classification, Light, Histochemical, and Electrón Microscopic Studies on Three Patients with the Erythema Dyschromicum Perstans Type. Int J Dermatol 1982;21:25-31.

  19. Soter N.A, Wands C, Freeman R.G. Ultrastructural Pathology of Erythema Dyschromicum Perstans. J Invest Dermatol 1969;52:155-161.

  20. Peachey R.D.G. South West of England and Wales Dermatology Society Ashy Dermatosis. J Dermatol 1976;94:227-8.

  21. Baranda L, Torres-Alvarez B, Cortes-Franco R, Moncada B, Portales Pérez D, González-Amaro R. Involvement of Cell Adhesion and Activation Molecules in the Pathogenesis of Erythema Dyschromicum Perstans (Ashy Dermatitis) The effect of Clozamine Therapy. Arch Dermatolol 1997;133:325-28

  22. Jack L. Arbiser, M.D., Samuel L. Moschella, M.D. Clofazimine: A Review of its medical uses and mechanisms of action. J Am Acad Dermatol 1995;32:241-7.




2020     |     www.medigraphic.com